Skip to content

Study · Not a test of the peptide alone · 1997

8 results

Effects of antagonists of growth hormone-releasing hormone (GHRH) on GH and insulin-like growth factor I levels in transgenic mice overexpressing the human GHRH gene, an animal model of acromegaly.

Kovacs M, Kineman RD, Schally AV, Zarandi M, Groot K, Frohman LA

Endocrinology1 Nov 1997Cited by 23 (Europe PMC)

PMID9348175 (opens in a new tab)DOI10.1210/endo.138.11.5498 (opens in a new tab)PepBankPUB-09348175
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone8

In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Sermorelin.

  1. 01AnimalNot a test of Sermorelin aloneAnimal study (in vivo)Activity measurement

    In MT-GHRH transgenic mice, single iv doses of MZ-4-71 and MZ-5-156 decreased serum GH by 39-72% at 1 h.

    In plain wordsIn mice with excess GHRH, one injection of either GHRH-blocking drug lowered blood growth hormone by 39 to 72% after one hour.

    Peptide
    Sermorelin
    Outcome
    DecreaseSerum GH after single iv antagonist dose
    Study

    mousen: not reported in source

    MT-GHRH transgenic mice overexpressing human GHRH
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Serum GH decrease
    39 to 72%
    1 h after iv antagonist

    Source sentences

    Summary
    To ascertain whether MZ-4-71 and MZ-5-156 could antagonize the effect of hGHRH hyperstimulation in vivo, each antagonist was administered to MT-GHRH transgenic mice in a single iv dose of 10-200 microg. Both compounds decreased serum GH levels in transgenic mice by 39-72% at 1 h after injection.
    1 context sentence
    Summary · context
    Transgenic mice overexpressing the human GH-releasing hormone (hGHRH) gene, an animal model of acromegaly, were used to investigate the effects of potent GHRH antagonists MZ-4-71 and MZ-5-156 on the excessive GH and insulin-like growth factor I (IGF-I) secretion caused by overproduction of hGHRH.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  2. 02AnimalNot a test of Sermorelin aloneAnimal study (in vivo)Activity measurement

    In MT-GHRH transgenic mice, the inhibitory effect of 50 microg MZ-5-156 on serum GH was maintained for 5 h.

    In plain wordsIn mice with excess GHRH, the growth hormone lowering effect of one dose of the GHRH-blocking drug MZ-5-156 lasted 5 hours.

    Peptide
    Sermorelin
    Outcome
    DecreaseDuration of MZ-5-156 effect on serum GH
    Study

    mousen: not reported in source

    MT-GHRH transgenic mice overexpressing human GHRH
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    The inhibitory effect of 50 microg MZ-5-156 was maintained for 5 h.
    1 context sentence
    Summary · context
    Transgenic mice overexpressing the human GH-releasing hormone (hGHRH) gene, an animal model of acromegaly, were used to investigate the effects of potent GHRH antagonists MZ-4-71 and MZ-5-156 on the excessive GH and insulin-like growth factor I (IGF-I) secretion caused by overproduction of hGHRH.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  3. 03AnimalNot a test of Sermorelin aloneAnimal study (in vivo)Activity measurement

    In MT-GHRH transgenic mice, twice daily ip MZ-5-156 for 3 days suppressed elevated serum GH by 56.8%.

    In plain wordsIn mice with excess GHRH, three days of the GHRH-blocking drug MZ-5-156 lowered raised blood growth hormone by 56.8%.

    Peptide
    Sermorelin
    Outcome
    DecreaseSerum GH after 3 days of MZ-5-156
    Study

    mousen: not reported in source

    MT-GHRH transgenic mice overexpressing human GHRH
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Serum GH decrease
    56.8%
    MZ-5-156 100 microg twice daily for 3 days

    Source sentences

    Summary
    Twice daily ip administration of 100 microg MZ-5-156 for 3 days suppressed the highly elevated serum GH and IGF-I concentrations in transgenic mice by 56.8% and 39.0%, respectively.
    1 context sentence
    Summary · context
    Transgenic mice overexpressing the human GH-releasing hormone (hGHRH) gene, an animal model of acromegaly, were used to investigate the effects of potent GHRH antagonists MZ-4-71 and MZ-5-156 on the excessive GH and insulin-like growth factor I (IGF-I) secretion caused by overproduction of hGHRH.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  4. 04AnimalNot a test of Sermorelin aloneAnimal study (in vivo)Activity measurement

    In MT-GHRH transgenic mice, twice daily ip MZ-5-156 for 3 days suppressed elevated serum IGF-I by 39.0%.

    In plain wordsIn mice with excess GHRH, three days of the GHRH-blocking drug MZ-5-156 lowered raised blood IGF-I by 39.0%.

    Peptide
    Sermorelin
    Outcome
    DecreaseSerum IGF-I after 3 days of MZ-5-156
    Study

    mousen: not reported in source

    MT-GHRH transgenic mice overexpressing human GHRH
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Serum IGF-I decrease
    39%
    MZ-5-156 100 microg twice daily for 3 days

    Source sentences

    Summary
    Twice daily ip administration of 100 microg MZ-5-156 for 3 days suppressed the highly elevated serum GH and IGF-I concentrations in transgenic mice by 56.8% and 39.0%, respectively.
    1 context sentence
    Summary · context
    Transgenic mice overexpressing the human GH-releasing hormone (hGHRH) gene, an animal model of acromegaly, were used to investigate the effects of potent GHRH antagonists MZ-4-71 and MZ-5-156 on the excessive GH and insulin-like growth factor I (IGF-I) secretion caused by overproduction of hGHRH.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  5. 05AnimalNot a test of Sermorelin aloneAnimal study (in vivo)Mechanism

    In MT-GHRH transgenic mice, MZ-5-156 reduced IGF-I messenger RNA levels in the liver by 21.8%.

    In plain wordsIn mice with excess GHRH, the GHRH-blocking drug MZ-5-156 lowered IGF-I messenger RNA in the liver by 21.8%.

    Peptide
    Sermorelin
    Outcome
    DecreaseLiver IGF-I mRNA after MZ-5-156
    Study

    mousen: not reported in source

    MT-GHRH transgenic mice overexpressing human GHRH
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Liver IGF-I mRNA decrease
    21.8%
    MZ-5-156 treatment

    Source sentences

    Summary
    This treatment also reduced IGF-I messenger RNA levels in the liver by 21.8%
    1 context sentence
    Summary · context
    Transgenic mice overexpressing the human GH-releasing hormone (hGHRH) gene, an animal model of acromegaly, were used to investigate the effects of potent GHRH antagonists MZ-4-71 and MZ-5-156 on the excessive GH and insulin-like growth factor I (IGF-I) secretion caused by overproduction of hGHRH.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  6. 06AnimalNot a test of Sermorelin aloneAnimal study (in vivo)Mechanism

    In MT-GHRH transgenic mice, MZ-5-156 did not affect GH messenger RNA levels in the pituitary.

    In plain wordsIn mice with excess GHRH, the GHRH-blocking drug MZ-5-156 did not change growth hormone messenger RNA in the pituitary.

    Peptide
    Sermorelin
    Outcome
    No significant changePituitary GH mRNA after MZ-5-156
    Study

    mousen: not reported in source

    MT-GHRH transgenic mice overexpressing human GHRH
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    but did not affect the level of GH messenger RNA in the pituitary.
    1 context sentence
    Summary · context
    Transgenic mice overexpressing the human GH-releasing hormone (hGHRH) gene, an animal model of acromegaly, were used to investigate the effects of potent GHRH antagonists MZ-4-71 and MZ-5-156 on the excessive GH and insulin-like growth factor I (IGF-I) secretion caused by overproduction of hGHRH.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  7. 07LabNot a test of Sermorelin aloneEx vivo tissueActivity measurement

    In superfused pituitary cells from MT-GHRH transgenic mice, the GHRH antagonists MZ-4-71 and MZ-5-156 suppressed basal GH release.

    In plain wordsIn pituitary cells from mice with excess GHRH, two GHRH-blocking drugs lowered growth hormone release in the lab.

    Peptide
    Sermorelin
    Outcome
    DecreaseBasal GH release from MT-GHRH pituitary cells
    Study

    mousen: not reported in source

    MT-GHRH transgenic mice overexpressing human GHRH
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    Both MZ-4-71 and MZ-5-156 suppressed basal release of GH from superfused MT-GHRH pituitary cells, apparently by blocking the action of endogenously produced hGHRH.
    1 context sentence
    Summary · context
    Transgenic mice overexpressing the human GH-releasing hormone (hGHRH) gene, an animal model of acromegaly, were used to investigate the effects of potent GHRH antagonists MZ-4-71 and MZ-5-156 on the excessive GH and insulin-like growth factor I (IGF-I) secretion caused by overproduction of hGHRH.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

  8. 08LabNot a test of Sermorelin aloneEx vivo tissueActivity measurement

    In pituitary cells from MT-GHRH mice, the antagonists effectively eliminated the response to stimulation by exogenous hGHRH(1-29)NH2.

    In plain wordsIn pituitary cells from mice with excess GHRH, two GHRH-blocking drugs removed the response to added GHRH in the lab.

    Peptide
    Sermorelin
    Outcome
    DecreaseResponse to exogenous hGHRH(1-29)NH2 in MT-GHRH pituitary cells
    Study

    mousen: not reported in source

    MT-GHRH transgenic mice overexpressing human GHRH
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    In addition, these antagonists effectively eliminated the response to stimulatory action of exogenous hGHRH(1-29)NH2 (30 and 100 nM).
    1 context sentence
    Summary · context
    Transgenic mice overexpressing the human GH-releasing hormone (hGHRH) gene, an animal model of acromegaly, were used to investigate the effects of potent GHRH antagonists MZ-4-71 and MZ-5-156 on the excessive GH and insulin-like growth factor I (IGF-I) secretion caused by overproduction of hGHRH.

    In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.